Hematologic Oncology

Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.

David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.

The FDA has lifted a partial clinical hold that was placed on a first-in-human, phase 1b trial evaluating RVU120 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Despite the failure of several strategies to improve the outcomes of patients with newly diagnosed diffuse large B-cell lymphoma, there appears to be substantial and growing progress in the treatment of relapsed disease.

The combination of eprenetapopt and azacitidine demonstrated a promising safety profile as well as encouraging clinical activity in a high-risk population of patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

Potential implications for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with loncastuximab tesirine, an antibody-drug conjugate, based on early results demonstrated by the LOTIS-2 study.

A historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy.

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center & Research Institute, discusses the importance of examining a patient’s complete blood count, nutritional status and bone marrow when considering a diagnosis of myelodysplastic syndrome.

Gail Roboz, MD; Azra Raza, MD; and Amy DeZern, MD, MHS, discuss the clinical considerations and risk assessments inherent to a diagnosis of myelodysplastic syndrome.

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

Jean-Jacques Kiladjian, MD, PhD, describes updated results presented at the European Hematology Association 2021 Virtual Congress from the phase 3 SIMPLIFY-1 trial of momelotinib vs ruxolitinib in JAK inhibitor–naïve patients with myelofibrosis.

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Ruben Mesa, MD, Director of UT Health San Antonio MD Anderson Cancer Center, presents data from the 2021 European Hematology Association Virtual Congress from the SIMPLIFY-1 and SIMPLIFY-2 trials of patients with myelofibrosis who were treated with momelotinib.

Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.

Sandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.

Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.

Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.

Primary investigator Bijal Shah, MD, MS, shares insights into the efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and Eunice Wang, MD, reviews the trial’s key safety data.

Leukemia experts provide an overview of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy in adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) by discussing the overall study design and patient population.

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

An independent data monitoring committee has recommended that the phase 3 ARMADA 200 trial examining devimistat plus high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia continue as planned.

The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as part of a chemotherapy regimen to treat pediatric and adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products.